PSVT is a disease with a significant unmet need

PSVT can significantly affect the quality of life of patients due to episodes of tachycardia that can come at any time without warning. Currently, there are no self-administered drug treatment options approved by the FDA to stop PSVT episodes when they start.

Find out more about PSVT

Milestone is committed to improving the lives of PSVT patients

For more than a decade, Milestone has been working to develop new therapies intended to stop PSVT episodes when they start.

Learn more about Milestone’s R&D program.

About Milestone

Milestone Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications.. The company’s lead product investigational candidate, etripamil (MSP-2017), is entering Phase 3 development. Etripamil is a new, potent, short-acting, investigational calcium channel blocker being developed as a rapid-onset nasal spray that can be self-administered to terminate paroxysmal supraventricular tachycardia (PSVT) episodes.

Learn More

Featured News & Events

Milestone Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference

Milestone Pharmaceuticals USA, Inc. today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2018 at 9:50 a.m. Eastern Time.

Read More | All News Stories